Mesoblast (MEOBF) Shares Outstanding (2014 - 2026)
Mesoblast's (MEOBF) quarterly Shares Outstanding (Entity) came in at $129.5 million in Q2 2026, up 1.16% year-over-year from $128.0 million in Q2 2025, and up 1.16% quarter-over-quarter from $128.0 million in Q2 2025.
Analysis
Mesoblast (MEOBF) Shares Outstanding (2014 - 2026) Analysis & Trends
Mesoblast has disclosed Shares Outstanding (Entity) across 13 years of filings, most recently posting $129.5 million for Q2 2026.
- In Q2 2026, Shares Outstanding (Entity) rose 1.16% year-over-year to $129.5 million; the TTM figure through Jun 2026 stood at $129.5 million (up 1.16% YoY), while the FY2026 annual figure was $129.5 million, up 1.16% from the prior year.
- Shares Outstanding (Entity) came in at $129.5 million for Q2 2026 at Mesoblast, up from $128.0 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $129.5 million in Q2 2026 to a low of $65.0 million in Q2 2022.
- Average Shares Outstanding (Entity) over 5 years is $103.6 million, with a median of $114.2 million recorded in 2024.
- Year-over-year, Shares Outstanding (Entity) climbed 0.27% in 2022 and surged 40.23% in 2024.
- Over 5 years, Shares Outstanding (Entity) stood at $65.0 million in 2022, then climbed by 25.17% to $81.4 million in 2023, then soared by 40.23% to $114.2 million in 2024, then climbed by 12.1% to $128.0 million in 2025, then grew by 1.16% to $129.5 million in 2026.
- Per Business Quant data, the three most recent Shares Outstanding (Entity) figures were $129.5 million in Q2 2026, $128.0 million in Q2 2025, and $114.2 million in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.42 Bn | 112.79 Mn | 29.53 Mn |
| 2 | CRISPR Therapeutics AG | 5.20 Bn | 5.20 Bn | - | 96.51 Mn |
| 3 | Iovance Biotherapeutics | 3.78 Bn | 3.49 Bn | 55.72 Mn | 450.19 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | 184.32 Mn |
| 5 | uniQure | 3.06 Bn | 3.06 Bn | 5.49 Mn | 66.24 Mn |
| 6 | Beam Therapeutics | 2.68 Bn | 2.68 Bn | - | 104.33 Mn |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | 356.89 Mn |
| 8 | Sarepta Therapeutics | 2.35 Bn | 1.55 Bn | 251.87 Mn | 105.43 Mn |
| 9 | Vericel | 2.00 Bn | 1.83 Bn | 56.40 Mn | 51.08 Mn |
| 10 | Mesoblast | 246.02 Mn | 143.11 Mn | - | 129.49 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 129.49 Mn |
| Dec 31, 2025 | 120.78 Mn |
| Jun 30, 2025 | 120.78 Mn |
| Dec 31, 2024 | 98.67 Mn |
| Jun 30, 2024 | 98.67 Mn |
| Dec 31, 2023 | 73.90 Mn |
| Jun 30, 2023 | 73.90 Mn |
| Mar 31, 2023 | 64.89 Mn |
| Dec 31, 2022 | 64.89 Mn |
| Sep 30, 2022 | 64.89 Mn |
| Jun 30, 2022 | 64.89 Mn |
| Mar 31, 2022 | 60.51 Mn |
| Dec 31, 2021 | 60.51 Mn |
| Sep 30, 2021 | 60.51 Mn |
| Jun 30, 2021 | 60.51 Mn |
| Mar 31, 2021 | 52.88 Mn |
| Dec 31, 2020 | 52.88 Mn |
| Sep 30, 2020 | 52.88 Mn |
| Jun 30, 2020 | 52.88 Mn |
| Mar 31, 2020 | 49.44 Mn |